摘要
Abstract
Objective:To investigate the effect of combined treatment with Ranibizumab and panretinal laser photocoagulation on vascular endothelial growth factor(VEGF),macular foveal retinal thickness(CMT)and nitric oxide(NO)in patients with central retinal vein occlusion(CRVO),and to provide a favorable reference for future clinical treatment of CRVO.Method:A total of 120 patients(120 eyes)with CRVO who admitted to Wuwei City Liangzhou Hospital from March 2020 to January 2024 were selected,and they were divided into the observation group and the control group by random number table method,with 60 cases(60 eyes)in each group.The control group was treated with panretinal laser photocoagulation,and the observation group was treated with Ranibizumab combined with panretinal laser photocoagulation.The efficacy,vascular endothelial function,CMT and adverse reactions were compared between two groups.Result:The total effective rate of the observation group was 96.67%,which was higher than 70.00%of the control group,and the difference was statistically significant(P<0.05);after treatment,the levels of VEGF and CMT in two groups were lower than those before treatment,and those in the observation group were lower than the control group,the levels of NO in two groups were higher than those before treatment,and that in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05);the total incidence of adverse reactions in the observation group was 3.33%,compared with 1.67%in the control group,the difference was not statistically significant(P>0.05).Conclusion:The combination of Ranibizumab and panretinal laser photocoagulation in patients with CRVO has a definite effect,which can reduce the levels of VEGF and CMT,increase the level of NO,and has high safety.关键词
雷珠单抗/全视网膜激光光凝/视网膜中央静脉阻塞/血管内皮生长因子/黄斑中心凹视网膜厚度/一氧化氮Key words
Ranibizumab/Panretinal laser photocoagulation/Central retinal vein occlusion/Vascular endothelial growth factor/Central macular thickness/Nitric oxide
